uploads/2016/07/analyst-recommendations-17-1.png

What Analysts Recommend ahead of BDX’s Fiscal 3Q16 Earnings

By

Updated

Analysts’ recommendations

Becton, Dickinson and Company (BDX) is set to release its fiscal 3Q16 earnings results on August 4, 2016.

In a Bloomberg survey of 19 brokerage companies taken on July 26, 2016, about 58% of analysts rated BDX as a “buy,” and 42% rated it as a “hold.” No analysts rated BDX as a “sell.”

The table above lists the 13 brokerage companies that have provided target prices for BDX for the next 12 months. The consensus 12-month target price for BDX is $182.5, amounting to a return potential of ~5.6% over BDX’s price of $172.8 on July 25, 2016.

On July 26, RBC Capital Markets gave BDX a one-year target price of $169, the company’s lowest target price. This target implies a -2.2% return over the next 12 months.

Among large investment banks, JPMorgan Chase gave BDX a one-year target price of $178, implying a ~3% return potential over the next 12 months. Raymond James gave BDX a one-year target price of $200, implying a ~15.7% return potential over the next 12 months.

Peers Boston Scientific (BSX), Medtronic (MDT), and Baxter International (BAX) have average broker target prices of $25.2, $92.9, and $48.9, respectively. These figures imply returns of 6.1%, 7%, and 6.1%, respectively, over the next 12 months.

Article continues below advertisement

ETFs with exposures to BDX

Investors can get exposure to BDX by investing in the PowerShares Dynamic Market ETF (PWC), which has 2.4% of its total holdings in BDX.

The SPDR S&P Dividend ETF (SDY) has ~0.69% of its total holdings in BDX. Investors can also gain exposure to BDX through the iShares U.S. Medical Devices ETF (IHI), which has 5.4% of its total holdings in BDX.

Advertisement

More From Market Realist